pharma · Amyotrophic Lateral Sclerosis · Pharmacokinetics · NRSN
NeuroSense Therapeutics
NeuroSense Therapeutics patent portfolio — 2 USPTO pharmaceutical patents (A61K/A61P) with grant dates, status, and loss-of-exclusivity filters.
Cambridge, USA HQ
2017 Founded
30 Employees
Public company Type
NRSN · NYSE Ticker
Company details
- Status
- Public
- HQ
- Cambridge, USA
- Founded
- 2017
- Employees
- 30
- Programs
- 6
- Drugs
- 6
- Patents
- 2
NeuroSense Therapeutics patents
2 pharmaceutical patents indexed for NeuroSense Therapeutics. 0 expire within 24 months.
NeuroSense Therapeutics has 2 pharmaceutical patents in our USPTO PatentsView index (A61K/A61P). 0 expire within 24 months — use filters for patent-cliff planning.
Patent portfolio
Frequently asked questions
How many patents does NeuroSense Therapeutics have?
2 published patents match the current filter (all indexed). The full portfolio is indexed from USPTO PatentsView (A61K/A61P).
When do NeuroSense Therapeutics patents expire?
0 patents in the full portfolio expire within 24 months. Use the expiring filters above or open individual patent pages for grant and expiration dates.